188 related articles for article (PubMed ID: 24549719)
1. Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β.
Fu Y; Zheng Y; Chan KG; Liang A; Hu F
Mol Biol Rep; 2014 Jun; 41(6):3907-13. PubMed ID: 24549719
[TBL] [Abstract][Full Text] [Related]
2. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Fu Y; Zheng Y; Li K; Huang R; Zheng S; An N; Liang A
Biotechnol Lett; 2012 Mar; 34(3):441-6. PubMed ID: 22105553
[TBL] [Abstract][Full Text] [Related]
3. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
[TBL] [Abstract][Full Text] [Related]
4. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
[TBL] [Abstract][Full Text] [Related]
5. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate.
Komotar RJ; Starke RM; Sisti MB; Connolly ES
Neurosurgery; 2010 Apr; 66(4):N20-1. PubMed ID: 20305482
[No Abstract] [Full Text] [Related]
7. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells.
Tanaka H; Sasayama T; Tanaka K; Nakamizo S; Nishihara M; Mizukawa K; Kohta M; Koyama J; Miyake S; Taniguchi M; Hosoda K; Kohmura E
J Neurooncol; 2013 Feb; 111(3):273-83. PubMed ID: 23263745
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
9. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
10. GSK-3β regulates tumor growth and angiogenesis in human glioma cells.
Zhao P; Li Q; Shi Z; Li C; Wang L; Liu X; Jiang C; Qian X; You Y; Liu N; Liu LZ; Ding L; Jiang BH
Oncotarget; 2015 Oct; 6(31):31901-15. PubMed ID: 26388612
[TBL] [Abstract][Full Text] [Related]
11. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
12. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
[TBL] [Abstract][Full Text] [Related]
13. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H; Ye D; Guan KL; Xiong Y
Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
[TBL] [Abstract][Full Text] [Related]
15. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
16. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
18. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
19. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
20. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
